drugset / Trial / NCT00003681
Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome
Treatment
Summary
RATIONALE: Amifostine may improve blood counts in patients with myelodysplastic syndrome. Epoetin alfa may stimulate red blood cell production and be an effective treatment for anemia in patients with myelodysplastic syndrome. PURPOSE: Phase II trial to study the effectiveness of amifostine with or without epoetin alfa in treating patients who have myelodysplastic syndrome.
Timeline
- Start
- 1998-08
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | amifostine | Unknown | — | Intravenous |
| Subject | epoetin alfa | Protein / enzyme biologic | — | Subcutaneous |